A new treatment approach can significantly improve the survival rate for patients with aggressive, inherited breast cancer, showing a study.

Cambridge includes testing under the ADANBROOKES hospital, and published in nature communications, women with early stage breast cancer, who have inherited BRCA1 or BRCA2 gene mutation.

Prior to surgery, giving them the targeted drug halparribe reduced the chances of cancer coming back.

In the UK, more than 1,200 patients in a year can benefit from changes in practice if a large clinical test can confirm the findings.

Hollywood star Angelina Jolie raised awareness about inherited breast cancer genes in 2013, when she had a double mastectomy to reduce her risk of disease.

Jackie Van Bachowen, a 59 -year -old Cambrisshire, has a family history of breast cancer and is a faulty copy of the BRCA1 gene, which greatly increases the risk of the disease during her lifetime.

He was detected an aggressive breast tumor in 2019 and participated in the test.

“When I had a diagnosis, I was completely surprised,” he told BBC News.

“Six years, I am well and cancer -free. It’s amazing.”

Both Jackie’s mother and sister had breast cancer. They have three daughters and also create the eldest, Daniel, inherited BRCA gene mutation.

“For my future generations, if they have received the BRCA gene, it is a new hope,” Jackie said.

One in about 400 people mutate in BRCA1 or BRCA2 genes.

Cancer Research UK estimates that seven out of seven women will develop breast cancer with changes in these genes, compared to one of the seven women without these mutations.

For men with BRCA mutations, the risks of breast cancer development are very low.

Olaparibe BRCA gene is the first targeted drug treatment for cancer with mutations and is given as a tablet. It works by preventing cancer cells from being able to repair its DNA by blocking a protein called Parp, causing cancer cells to die.

The trial, named Partner, took place on 23 sites in England, Scotland and Wales. Prior to surgery, 39 women with early stages breast cancer were given hailparibe, also known as linapurza, along with chemotherapy.

He started hailproid bullets 48 hours after each chemotherapy infusion. Three years later, all survived.

In contrast, the study led to six deaths in 45 women, who received chemotherapy before surgery, but did not find Olaparib.

Professor, Jean Abraham, an advisor to Adenbrooks and Professor of Professor of Professor Breast Cancer Medicine at the University of Cambridge, who led the test described the results as “really exciting”.

“It is rare that you see 100% existence in 36 months for this subtlety of breast cancer. We are incredibly excited about the ability of this new approach.”

The findings have the ability to apply to other BRCA -related cancer, such as ovarian, prostate and pancreatic. ,

Professor Abraham said that a large, multinational test is planned next year, including some 600 patients. They predicted that if the findings are repeated, it would be a major change in clinical practice for more than 1,200 patients in the UK a year.

Currently, patients are given hailparfibe for one year after surgery, while patients took bullets at surgery and half doses 12 weeks ago on test.

Professor Abraham said: “From a cost perspective, it will save a lot of amount to NHS as it is a fraction of drug time and dose.”

Cancer Research UK CEO Mitchell Mitchell said: “While this research is still in its early stages, it is an exciting discovery that carefully adding Olaparibe to the treatment can potentially be given more time with their loved ones with this specific type of breast cancer.